US2008319174A1PendingUtilityA1

Chimera humanized vascular endothelial growth factor

Assignee: SHIBUYA MASABUMIPriority: Aug 10, 2000Filed: Jun 19, 2008Published: Dec 25, 2008
Est. expiryAug 10, 2020(expired)· nominal 20-yr term from priority
A61K 48/00A61K 38/00A61P 9/10A61P 9/00C07K 14/52C07K 2319/00
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An object of the present invention is to provide a chimera VEGF-E having a reduced antigenicity while maintaining the activity of VEGF-E. The present invention provides a chimera protein having an activity of growing vascular endothelial cells, which is obtained by substituting a part of the sequence of a VEGF analogous protein having an activity of vascularization that binds to KDR (VEGF receptor-2) but does not bind to Flt-1 (VEGF, receptor-1) with a corresponding sequence of a human-derived VEGF analogous protein.

Claims

exact text as granted — not AI-modified
1 . A chimera protein which has any of the amino acid sequences shown below:
 (A) the amino acid sequence which is obtained by deleting 1-20 amino acids of signal peptide at the amino-terminal region of the amino acid sequence as shown in SEQ ID NO: 15, or   (B) the amino acid sequence as shown in (A), in which one to ten amino acids are deleted, substituted, and/or added and which has an activity of growing vascular endothelial cells.   
     
     
         2 . A chimera protein which has any of the amino acid sequences shown below:
 (A) the amino acid sequence which is obtained by deleting 6 amino acids of histidine-tag at the carboxyl-terminal region from the amino acid sequence as shown in SEQ ID NO: 15, or   (B) the amino acid sequence as shown in (A), in which one to ten amino acids are deleted, substituted, and/or added and which has an activity of growing vascular endothelial cells.   
     
     
         3 . A chimera protein which has any of the amino acid sequences shown below:
 (A) the amino acid sequence which is obtained by deleting 1-20 amino acids of signal peptide at the amino-terminal region and 6 amino acids of histidine-tag at the carboxyl-terminal region from the amino acid sequence as shown in SEQ ID NO: 15, or   (B) the amino acid sequence as shown in (A), in which one to ten amino acids are deleted, substituted, and/or added and which has an activity of growing vascular endothelial cells.   
     
     
         4 . The chimera protein according to  claim 3 , wherein the amino acid sequence is obtained by deleting 1-15 amino acids of signal peptide at the amino-terminal region and 6 amino acids of histidine-tag at the carboxyl-terminal region from the amino acid sequence as shown in SEQ ID NO: 15. 
     
     
         5 . The chimera protein according to  claim 3 , wherein the amino acid sequence is obtained by deleting 1-10 amino acids of signal peptide at the amino-terminal region and 6 amino acids of histidine-tag at the carboxyl-terminal region from the amino acid sequence as shown in SEQ ID NO: 15. 
     
     
         6 . The chimera protein according to  claim 3 , wherein the amino acid sequence is obtained by deleting 1-5 amino acids of signal peptide at the amino-terminal region and 6 amino acids of histidine-tag at the carboxyl-terminal region from the amino acid sequence as shown in SEQ ID NO: 15.

Join the waitlist — get patent alerts

Track US2008319174A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.